Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome. by Eakins, R et al.
1Scientific RepoRts | 5:16423 | DOI: 10.1038/srep16423
www.nature.com/scientificreports
Adaptation to acetaminophen 
exposure elicits major changes in 
expression and distribution of the 
hepatic proteome
R. Eakins1,*, J. Walsh1,*, L. Randle2,*, R. E. Jenkins1, I. Schuppe-Koistinen3, C. Rowe1, 
P. Starkey Lewis1, O. Vasieva4, N. Prats5, N. Brillant1, M. Auli5, M. Bayliss1, S. Webb1, 
J. A. Rees1, N. R. Kitteringham1, C. E. Goldring1 & B. K. Park1
Acetaminophen overdose is the leading cause of acute liver failure. One dose of 10–15 g causes 
severe liver damage in humans, whereas repeated exposure to acetaminophen in humans and 
animal models results in autoprotection. Insight of this process is limited to select proteins 
implicated in acetaminophen toxicity and cellular defence. Here we investigate hepatic adaptation to 
acetaminophen toxicity from a whole proteome perspective, using quantitative mass spectrometry. 
In a rat model, we show the response to acetaminophen involves the expression of 30% of all 
proteins detected in the liver. Genetic ablation of a master regulator of cellular defence, NFE2L2, 
has little effect, suggesting redundancy in the regulation of adaptation. We show that adaptation to 
acetaminophen has a spatial component, involving a shift in regionalisation of CYP2E1, which may 
prevent toxicity thresholds being reached. These data reveal unexpected complexity and dynamic 
behaviour in the biological response to drug-induced liver injury.
Acetaminophen (paracetamol, APAP) overdose is the leading cause of acute liver failure in the USA 
and UK, resulting in over 600 deaths a year in these countries1,2. Whilst a single dose of 10–15 g is 
likely to result in severe liver damage3, prolonged exposure to acetaminophen has been shown to result 
in autoprotection in some patients, such that daily doses even in excess of 10 g have apparently little 
adverse effect. In one extreme example, APAP-induced autoprotection was demonstrated in an adult 
male addicted to the analgesic Percocet (APAP formulated with oxycodone), who consumed up to 65 g 
per day of APAP4. In addition, volunteers administered a daily therapeutic dose (4 g) of APAP dis-
played elevations in circulating liver enzymes (clinical markers of liver injury), which then resolved5. 
Autoprotection is therefore likely to be an important human defensive mechanism to prevent progressive 
injury resulting from drug toxicity.
Autoprotection to APAP has also been recapitulated in animal models: in mice, daily escalating doses 
can tolerize against liver damage within a week of treatment4. Our knowledge of the mechanism of 
hepatic adaptation is limited, and focus to date has been on select proteins implicated in APAP tox-
icity. APAP liver damage is caused by a metabolite – N-acetyl-p-benzoquinoneimine (NAPQI) – thus 
enzymes involved in the formation or detoxification of NAPQI are likely to be involved in the adaptive 
response. In particular, cytochrome P450 (CYP) 2E1 which activates APAP to NAPQI and the multidrug 
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resistance-associated proteins ABCC3 and ABCC4 (also known as MRP3 and MRP4), which transport 
APAP and other xenobiotics out of cells, have been implicated in the autoprotection4,6. Alternatively, 
proteins involved in the cell’s natural defence systems, including those regulating glutathione (GSH), may 
underlie the adaptation. A recent microarray study also linked the expression of a number of novel genes 
to the development of tolerance to APAP7. Induction of flavin-containing monooxygenase-3 (FMO3), 
an enzyme identified in this study that has not previously been associated with APAP metabolism, was 
subsequently shown to be protective in an APAP autoprotection model8.
Here, using a rat model, we have investigated this process and show that in fact the expression of as 
many as 30% of all proteins detected in the liver is altered during adaptation to APAP, and see a dramatic 
shift in the localisation of CYP2E1. This indicates that the process of adaptation to APAP-induced liver 
injury is more extensive and dynamic than previously thought.
Results
We examined two separate species, rat and mouse, for adaptation to repeat APAP exposure, in order to 
ensure that this is not a species-selective process and therefore more likely to be relevant to man. The two 
models were selected because of the similar sensitivity of the rat to human APAP hepatotoxicity9–11, and 
because the mouse is more amenable to genetic modification in order to test the role of specific genes 
in the process. Rats were dosed orally with 500, 1000 or 1500 mg/kg APAP, and mice with 250, 500 or 
750 mg/kg APAP. The doses were chosen in order to monitor autoprotection across a range of sub-toxic, 
threshold toxic and overtly toxic doses of APAP, to ensure that the drug exposure is relevant to what may 
occur in humans. Animals were either dosed once at 0 h with sacrifice at 2 h or 24 h, or at 24 h intervals 
for up to 72 h and sacrificed 24 h after the final dose administered. An outline of the dosing protocol 
is shown in Fig.  1a. At the 1500 mg/kg dose, at 48 h, rats exhibited rises in circulating liver enzymes, 
showing a peak serum alanine aminotransferase (ALT) rise 36-fold above vehicle controls, and a 33-fold 
serum aspartate aminotransferase (AST) rise over control (Fig. 1b,c). Both markers returned to normal 
levels by 96 h. Histopathology analyses were performed in order to validate the model of liver injury (rep-
resentative images are shown, Fig. 1d). Although substantial hepatocellular damage was seen at 48 h, this 
injury had largely resolved by 72 h, despite the animals continuing to receive a daily toxic dose of APAP.
At the 750 mg/kg dose of APAP, at 48 h, mice also displayed a peak serum ALT rise, which reached 
200-fold above vehicle controls, and a 67-fold serum AST rise over control (Fig. 1e,f). Both markers also 
returned to normal levels by 96 h. Although substantial hepatocellular damage was seen at 48 h (Fig. 1g), 
this injury had resolved considerably by 72 h, as in the rat model.
In order to reveal the breadth of change occurring in the liver during adaptation, we selected the rat 
model for comprehensive analysis using a global bioanalytical approach. While ALT levels were signif-
icantly elevated at 48 h in the rat (as they were in the mouse), indicative of substantial hepatocellular 
damage, the degree of overt liver tissue degeneration was low (in contrast to the mouse) as assessed 
by histopathology, thus allowing robust proteomic analysis. The technique of isobaric tags for relative 
and absolute quantification (iTRAQ) allows unambiguous identification and quantification of proteins 
expressed in a complex tissue matrix, and presents here a snapshot of the hepatoproteome at each of the 
time-points examined. Analysis of rat liver identified 2181 unique proteins, of which 1169 were common 
to all animals and all time-points, and were therefore amenable for statistical analysis and pathway map-
ping. Lists of significantly altered proteins are shown in Supplementary Tables 1a–d.
Global changes at each time-point were visualised as volcano plots (Fig. 2a–d), in which significance 
(y) is plotted against fold change (x). Although changes can be seen at 24 h (Fig. 2a), at 48 h (Fig. 2b; peak 
toxicity) the volcano plots show the greatest change in protein abundance, as indicated by the number 
of blue points (raw p < 0.05) and red points (FDR ≤ 0.05). Large numbers of protein changes are still 
observed at 72 h (Fig. 2c) and 96 h (Fig. 2d). Principal Component (PC) analysis was performed to iden-
tify the proteins contributing to the clearest differences in the data set as a whole (Fig. 2e). Comparing 
PC1 to PC4 allowed separation into three distinct groups (in Fig.  2e, see control and 24 h to the top 
right, 48 h and 72 h to top left, and 96 h to the bottom of the plot), thereby identifying groups of pro-
teins contributing to the major differences between these groups (Fig.  2e). These proteins are listed in 
Supplementary Table 2. Numerical descriptions of significant changes are shown in Table 1.
The subset of 1169 proteins common to all animals at every time-point is expressed as a heat map 
(Fig. 2f), which demonstrates the similarity in protein expression levels between control and single dose 
livers (24 h). By contrast, the profile of the same proteins in the repeat dose livers (48 h and 72 h) appears 
markedly changed. By 96 h a further shift in the protein expression profile is seen, consistent with the 
clustering shown in Fig. 2e. These observations are consistent with immunoblot data carried out on four 
proteins (Fig.  2g), selected from the mass spectrometric data for their different properties as sentinels 
of metabolic function or regeneration: Glutathione S-transferase P1 (GSTP1), NAD(P)H dehydroge-
nase [quinone] 1 (NQO1), Proliferating cell nuclear antigen (PCNA), and vimentin (VIM). NQO1 and 
GSTP1 are important enzymes in the detoxification of NAPQI, the toxic metabolite of APAP. PCNA is 
a marker of replication12, and indicates a surge in proliferative activity in the rats which peaks at 72 h. 
VIM is a classical marker of progenitor cells and is upregulated in cells that are undergoing epithelial to 
mesenchymal transition, a process implicated in wound healing and organ fibrosis13,14. Overall, the data 
indicate a much wider response in adaptation than has been posited previously, not only implicating 
proteins directly involved in APAP metabolism.
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Figure 1. Autoprotection occurs in the rat and the mouse following repeat acetaminophen exposure. 
(a) Dosing protocol used in the study. (b) ALT and (c) AST were determined in rat serum (n = 6). Both 
biomarkers were significantly elevated in the 1500 mg/kg dose group alone (ANOVA with Tukey post-test, 
***p < 0.001; 500 mg/kg circle, 1000 mg/kg square, 1500 mg/kg triangle, vehicle control diamond). (d) H&E 
staining of liver slices for groups of rats at each time-point in 1500 mg/kg group showed progression of 
injury (n = 4, representative images shown). (e) ALT and (f) AST were determined in mouse serum (n = 6). 
Both biomarkers were significantly elevated in the 750 mg/kg dose group alone (ANOVA with Tukey post-
test, ***p < 0.001; 250 mg/kg circle, 500 mg/kg square, 750 mg/kg triangle, vehicle control diamond).  
(g) H&E staining of liver slices for groups of mice at each time-point in 750 mg/kg group showed 
progression of injury (n = 4, representative images shown).
www.nature.com/scientificreports/
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Ingenuity pathway analysis identified the top twenty-five most perturbed canonical pathways during 
the process of adaptation to APAP (Fig. 3, a full list of proteins is shown in Supplementary Table 3). The 
changes highlight alterations in pathways that could be anticipated in our model, e.g. NFE2L2-mediated 
oxidative stress response and the acute phase response and others that were unexpected, e.g. melatonin 
degradation and dopamine degradation. This indicates, on a pathway-scale, that autoprotection to APAP 
involves a range of liver processes that are much more diverse than previously recognised.
Figure 2. Widespread changes in protein abundance occur in rat liver following repeated 
acetaminophen exposure. (a–d) Volcano plots of all common proteins quantified by iTRAQ analysis, at 
each time-point (a) 24 h, (b) 48 h, (c) 72 h, (d) 96 h, relative to vehicle control. A complete list is provided in 
Supplementary Tables 1a–d. Coloured circles represent differential expression (blue - raw P value, p < 0.05; 
red – FDR, p ≤ 0.05). (e) Principal Components Analysis identified the greatest differences between single 
and repeat dose samples. (f ) Heat map representing the 1169 proteins common to all samples and all time-
points identified distinct changes in protein abundance in repeat-dosed animals (red indicates increased 
abundance, blue indicates decreased abundance). (g) Western blots for GSTP1, NQO1, PCNA and VIM, 
performed in order to validate proteomic findings. Representative blots of two rats at each time-point are 
shown. Actin was used as a loading control.
www.nature.com/scientificreports/
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Changes in the proteins responsible for the disposition of most drugs, the so-called Phase I, II and 
III proteins, were explored in more depth (Fig. 4a–d). Thirteen out of the twenty-three quantified CYP 
enzymes, the single most important set of proteins that govern how the liver initially processes a drug, 
were found to be present at lower abundance at 48 h. This included CYP2E1, which is largely expressed 
in the centrilobular region of the liver and CYP2C6, which is expressed across all zones of the liver (36% 
and 30% of control values, respectively), although both of these proteins increased after 96 h (Fig. 4a,b). 
The majority of detected phase I and II proteins decreased during the process of adaptation to APAP. 
Notable exceptions to this were NQO1 and GSTP1. Both of these enzymes were more abundant at 48 h 
(273% and 269% of control values respectively, Fig. 4c), as well as at 96 h (Fig. 4d). The profound changes 
in the phenotype of the liver shown here after two successive doses of APAP are likely to influence the 
fate of subsequent APAP exposure. Importantly, there was no evidence from analysis of intrahepatic 
albumin expression for a global loss of hepatocytes during the process of adaptation to APAP (Fig. 4e). 
Timepoint 
(h)
Doses 
administered
Proteins increased 
abundance (p < 0.05)
Proteins decreased 
abundance (p < 0.05) Total
Percentage of quantifiable 
proteome
24 1 30 43 73 6.24
48 2 116 199 315 26.95
72 3 111 145 256 21.90
96 4 86 125 211 18.05
Table 1.  Relative changes in protein abundance in rat liver in response to repeat acetaminophen 
exposure. The number of proteins that were increased or decreased in abundance in rat liver at each 
timepoint compared to control animals is indicated. The total number of changed proteins is expressed as a 
percentage of the total number of proteins quantified in the analysis (1169).
Figure 3. Analysis of the rat liver proteome reveals widespread pathway changes in response to repeat 
acetaminophen exposure. Ingenuity pathway analysis showing the top twenty-five most perturbed canonical 
pathways during the process of adaptation to APAP exposure. The left panel shows the significance of 
increased abundance proteins and the right panel show significance of reduced abundance proteins. The 
final column denotes the number of unique proteins identified per canonical pathway. Lists are shown in 
Supplementary Table 3. Values in red are significant with colour intensity proportional to significance.
www.nature.com/scientificreports/
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Figure 4. Investigation of key liver pathways identified by proteomic analysis in response to repeat 
acetaminophen exposure. In rats, while the abundance of phase I (CYP450) proteins at (a) 48 h and (b) 96 h, 
and phase II and III proteins at (c) 48 h and (d) 96 h was altered compared to control, serum albumin (e) 
remained statistically unchanged throughout the timecourse. Bars represent mean protein abundance (n = 3–4; 
percentage of control + SEM). Dashed lines indicate mean control value. Statistical analysis was performed 
using a linear model in the R programming environment (ANOVA with Dunnett’s post-test, *p < 0.05, 
**p < 0.01, ***p < 0.001). (f) Survival of NFE2L2+/+ and NFE2L2−/− mice in APAP adaptation study. Bar chart 
comparing survival of toxic challenge after APAP or saline (0.9%) pretreatment in NFE2L2+/+ or NFE2L2−/− 
animals. Mice were pretreated with incremental doses of APAP ranging from 150–600 mg/kg i.p. or vehicle 
control for 8 days followed by a final challenge of 1000 mg/kg APAP or vehicle on day 9.
www.nature.com/scientificreports/
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Together with the ALT and histopathology data (Fig. 1), these observations indicate that although there 
is evidence of significant injury at 48 h, with key protein changes, albumin, a classical marker of liver 
function, remains invariant.
To look at the level of redundancy in the process of autoprotection to APAP, we then investigated 
the role of one of the key processes identified by pathway analysis, as described above, namely the 
‘NFE2L2-mediated Oxidative Stress Response’. Nuclear factor erythroid 2-related factor 2 (NFE2L2; also 
known as NRF2) is a transcription factor that has been shown to play a vital role in the cytoprotective 
response against the type of oxidative and chemical stresses elicited by APAP15–19. We therefore employed 
a genetic strategy to test the hypothesis that interference with such a key pathway would affect the 
outcome of the adaptive response. The effect of pre-treatment with APAP on the ability of NFE2L2+/+ 
and NFE2L2−/− mice to withstand a toxic challenge was investigated. All NFE2L2+/+ mice pre-treated 
with APAP survived a toxic challenge of APAP, whereas only 50% of NFE2L2+/+ mice which were not 
APAP-pre-treated survived (Fig.  4f). Amongst the NFE2L2−/− mice, whilst none of the animals which 
were not APAP-pre-treated survived, 50% of animals which were APAP-pre-treated survived, despite 
NFE2L2 deletion. The effect of APAP pre-treatment on the ability of NFE2L2+/+ and NFE2L2−/− mice 
to withstand a toxic challenge is summarised (Fig. 4f), and shows that in both wild type and NFE2L2−/− 
mice, APAP pre-treatment increases survival upon toxic challenge, i.e. in the absence of a key liver 
defence pathway, adaptation still occurs. This clearly demonstrates for the first time that it is unlikely that 
a single gene or pathway underlies the complexities of the adaptive process to APAP exposure.
In fact, when we looked in greater detail at another of the key changes visualized in our proteomic 
analysis, we determined that the process of autoprotection is yet more complicated than straightforward 
changes in the expression of a specific protein. Our proteomic data for CYP2E1 (Fig. 4a,b) looked to be 
particularly pertinent in the process of adaptation to APAP, as it shows a loss of the pre-eminent metab-
olising enzyme responsible for formation of the toxic metabolite of APAP (NAPQI). We therefore looked 
at the metabolism of both APAP (Fig. 5a) and the CYP2E1 probe substrate chlorzoxazone (Fig. 5b) in our 
rat model. Whilst overall APAP metabolism was significantly increased at 96 h (Fig. 5a), specific CYP2E1 
activity was reduced at 48 h and increased at 96 h (Fig. 5b). Relative CYP2E1 activity was 0.78 at 48 h, and 
1.43 at 96 h, compared to control (arbitrary value of 1). These findings, which mirrored our proteomic 
data for CYP2E1, indicated the potential for an increase in the generation of NAPQI in vivo, which was 
difficult to resolve with the observed process of adaptation to repeated exposure.
We therefore employed immunohistochemical techniques to further probe the expression of CYP2E1. 
In fact, CYP2E1 is shown to undergo a profound change in its distribution within the liver during the 
process of adaptation to APAP (Fig. 5c). Basally, CYP2E1 is mainly expressed in centrilobular regions. 
Upon APAP challenge, CYP2E1 staining becomes diffuse and extends into midzonal regions. Two doses 
produce acute centrilobular necrosis, with markedly reduced CYP2E1 staining in centrilobular regions. 
At later time-points, staining extends diffusely into periportal regions which are CYP2E1-negative in 
control animals. This is clear evidence that the process of adaptation to APAP is yet more complex than 
wide-scale changes in the hepatoproteome, and may also involve a regional reprogramming of gene 
expression in a key step in APAP metabolism. This would not be detected if protein abundance alone 
was measured (Fig.  5d), which shows overall loss and re-establishment of liver CYP2E1, as predicted 
from the proteomic data (Fig. 4a,b). This re-direction of phase I metabolism towards the periportal areas 
of the liver, where the levels of the reducing buffer GSH are highest, is likely to be hepatoprotective. 
Critically, when we looked at expression of another protein which is highly abundant in the centrilobular 
region, glutamine synthetase (GLUL) we did not see the same change (Fig. 5d), showing some degree of 
selectivity in the restoration of adaptive liver function. This is the first time that a regio-spatial control 
of expression of a gene, specifically with respect to hepatic APAP autoprotection, and generally as part 
of a response to a pharmaceutical agent, has been shown. A graphical summary is presented in Fig. 5e 
and shows the evolution of key aspects of the adaptive process in this model.
Discussion
Drug induced liver injury (DILI) is a major problem both in the clinic and for the pharmaceutical 
industry. Our relative lack of understanding of the physiological and toxicological mechanisms involved 
can lead to the loss of potentially effective drugs during development. APAP poisoning is itself also 
a significant clinical problem1,2. Furthermore, APAP is probably the best characterised hepatotoxin in 
pre-clinical models, and therefore provides a means to interrogate the various processes of adaptation 
and regeneration in the liver, which are also relevant to man and may be applicable to other drugs asso-
ciated with DILI.
In our model of APAP autoprotection, significant hepatotoxicity was only observed at a dose of 
1500 mg/kg, confirming that the rat is relatively resistant to APAP toxicity as reported earlier20–22. While 
hepatotoxicity was evident at 48 h (35% cell death, p < 0.001, data not shown), significantly less or no 
necrosis was observed at 72 and 96 h, despite repeated exposure to APAP. Liver function was maintained 
at these points, as assessed by serum transaminases and albumin synthesis. These observations demon-
strate an adaptive response in this model, protecting the liver from further injury, and this adaptation 
involves changes in a very large proportion of the expressed hepatoproteome.
Our data during the early phase of the development of the model, confirms previous studies which 
have shown that hepatic CYP2E1, the predominant enzyme involved in APAP metabolism and CYP1A2, 
www.nature.com/scientificreports/
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Figure 5. Rat liver CYP2E1 activity and localisation changes in response to repeat acetaminophen 
exposure. Microsomal formation of (a) APAP-GSH and (b) 6′-OH chlorzoxazone in animals which were 
either vehicle control treated, or repeat dosed with or without toxicity. Microsomal CYP2E1 activity is 
reduced in toxic (48 h treated, red squares) group and increased in non-toxic (96h treated, blue triangles) 
group compared to control (black circles). APAP metabolism is significantly higher in non-toxic (96h 
treated) group (**p < 0.01, ***p < 0.001, ****p < 0.0001). Best fit curves for each group (solid lines) were 
modelled using literature values for Km and Vmax. (c) Top panel shows representative IHC staining for 
CYP2E1 across the timecourse; bottom panel shows H&E stain. CV indicates central vein, while PT 
indicates the portal triad. CYP2E1 redistributes markedly as the timecourse progresses. (d) Densitometric 
analysis of total liver GLUL, CYP2E1 and actin detected by western blot, showing preferential restitution 
of CYP2E1 abundance over the similarly centrilobular glutamine synthetase (*p < 0.05, **p < 0.01, 
***p < 0.001). (e) Graphical summary of the model.
www.nature.com/scientificreports/
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which also plays a minor role in APAP metabolism23,24, are depleted, whilst the rate-limiting enzyme 
involved in the formation of the protective tripeptide GSH, i.e. glutamate-cysteine ligase regulatory 
subunit (GCLC)6,25, is increased, after pre-treatment with APAP. These proteins are likely to contribute 
to protection from toxicity, by reducing the CYP-catalysed bioactivation of APAP to NAPQI, and by 
increasing detoxification of NAPQI through enhanced synthesis of GSH. However, in this study, which 
is the first to formally and quantitatively assess over one thousand liver proteins from an in vivo model 
during adaptation to chemical exposure, we can now see that these changes are only one small part of a 
greatly altered and dynamic phenotype.
The change in the hepatoproteome may enable an adaptation that prevents toxicity from subsequent 
doses of APAP and maintains normal liver function despite repeated exposure to a toxic dose. Although 
Fig. 3, showing the top 25 most perturbed canonical pathways, indicates widespread loss of protein abun-
dance, particularly at the peak of toxicity, a number of pathways showed increased abundance, including 
‘acute phase response signalling’, ‘NFE2L2-mediated oxidative stress response’ and ‘glutathione-mediated 
detoxification’ which are all well-characterised reactions to toxic injury. We therefore employed a con-
ventional reductionist approach to examine in greater detail the role of transcription factor NFE2L2 in 
the process of adaptation. Whilst NFE2L2−/− mice showed a greater susceptibility to APAP toxicity com-
pared to wild types, after pretreatment with APAP an adaptive response was still evident in the absence 
of NFE2L2, albeit to a lesser degree. NFE2L2-mediated transcription is therefore not the only mechanism 
of adaptation to repeated toxic insult in this model, and provides a demonstration that the process of 
adaptation is more wide-ranging than previously thought.
Beyond confirming existing knowledge that several CYPs relevant to APAP metabolism are 
down-regulated upon repeat APAP exposure, we have shown that liver tissue from repeat dosed rats 
shows a significantly reduced abundance of proteins across all phases of drug metabolism (Fig. 4a–d). We 
hypothesise that this reduction in expression represents a key facet of adaptation, and provides an envi-
ronment which facilitates compensatory hyperplastic activity, preserving critical function. At the peak of 
toxicity, the mean of all detected CYPs is reduced to approximately 60% of control values. This change 
in phenotype is likely to be, at least partly, a consequence of the changing cell population in the liver 
over time. The initial toxic insult clearly destroys vulnerable hepatocytes at the centre of the lobule. CYP 
enzymes show predominantly centrilobular expression, and the differential expression of CYPs in intact 
zones may account for the overall change seen at 48 h. Nevertheless, a number of CYPs are pan-zonally 
expressed in rat liver26, and of the ones that are also identified in the present work (1A, 2B, 2C6 and 2C7, 
a close homologue of the pan-zonal CYPEtOH2 enzyme27–30), all are significantly less abundant at 48 h, 
dropping to around 30% of control (with the exception of 2C7 which is not significantly changed). This 
suggests an active change in the phenotype of intact cells, as has been previously postulated, indicating 
a global dedifferentiation resulting in decreased liver-specific protein expression as part of an adaptive 
response to injury31,32, rather than a passive destruction of CYP-rich tissue.
To further elucidate the complex mechanism of adaptation, we focused on CYP2E1 activity and local-
isation in response to repeat APAP exposure. Consistent with proteomic data obtained for CYP2E1 
abundance, microsomal activity assays show a loss of activity at 48h when acute injury is seen. Despite 
continued APAP exposure, however, at 96h a rebound of both expression and activity of CYP2E1 is seen 
(Fig. 5b,d). This is not consistent with the fall in toxicity observed after 48 h (Fig. 1). We therefore exam-
ined the tissue histologically, and identified a diffuse redistribution of CYP2E1 into CYP2E1-negative 
regions (Fig.  5c). Importantly, the loss and restoration of total liver 2E1 was not observed for another 
similarly perivenous enzyme, glutamine synthetase (Fig. 5d), suggesting that this process is selective. We 
hypothesise from these observations that, as a defence mechanism, diffuse expression of CYP2E1 may 
prevent the intracellular threshold of NAPQI toxicity being reached, thereby avoiding the initiation of 
further waves of cell death at later timepoints. Furthermore, in the regions where NAPQI is generated 
after redistribution of CYP2E1 expression, there are known to be higher intracellular concentrations of 
the reducing buffer GSH33. This phenomenon of CYP2E1 redistribution as an adaptive response has only 
been seen after treatment with carbon tetrachloride34 and ethanol35, but has not been detected previously 
after treatment with any pharmaceutical compound.
Proliferating liver demonstrates enhanced resistance to toxicity4,25,36, but the precise mechanism by 
which this occurs is unclear. Consistent with the findings presented here, rats which have been pretreated 
with APAP show signs of a regenerative hepatocyte response, determined through expression of PCNA, 
upon a second toxic challenge25. It has been shown that these new hepatocytes have a greater capacity 
for GSH production, allowing regenerating liver to detoxify NAPQI more efficiently25, but this hypothesis 
needs to be investigated in our model. Furthermore, a single dose of APAP has been shown to induce the 
expression of the transporter protein ABCC4 in proliferating hepatocytes, peaking at 48 h after dosing6. 
A number of transporters were detected in the current work, and of those that were changed, all were 
decreased in abundance at 48 h and onwards. A list of the transporters can be found in Supplementary 
Table 4. This may demonstrate a change in the liver phenotype away from drug metabolism and towards 
self-preservation and regeneration. A single dose control experiment was also performed in our study, 
and this showed a similar profile of toxicity to the repeat dose group (Supplementary Fig. 1). When 
experimental animals were given subsequent exposures, this toxicity was not exacerbated, indicating that 
a single exposure is all that is required to initiate liver adaptive processes.
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How these observations relate to the likely hepatic changes seen during chronic dosing in humans will 
be a key next step in this work. The identification of accessible translational biomarkers that can be used 
in rodents and man37,38 will be necessary to examine whether this process occurs in man at therapeutic 
doses of APAP, as well as with other drugs than can cause DILI.
Materials and Methods
Materials. 8-plex iTRAQ protein labelling kit/reagents were from AB Sciex (Framingham, MA). 
Sequencing grade trypsin was from Promega UK (Southampton, UK). PCNA, GLUL and NQO1 anti-
bodies were from Abcam (Cambridge, UK; cat. no. ab29, ab49873 and ab2346 respectively). VIM anti-
body was from Sigma (St. Louis, MO; cat. no. V6389). GSTP1 antibody was from Enzo Life Sciences 
(Farmingdale, NY; msa-102). CYP2E1 antibody was kindly provided by Magnus Ingelman-Sundberg, 
Karolinska Institute, Sweden. Parent drugs for LC-MS analysis were obtained from Sigma-Aldrich 
(Gillingham, UK), internal standards from Toronto Research Chemicals (Toronto, Canada) and Alsachim 
(Illkirch-Graffenstaden, France). Metabolites were obtained from the same sources. All other reagents 
were of analytical grade and quality and purchased from Sigma (St. Louis, MO).
Animals. Male Crl:WI (Han) rats and Crl:CD1 (ICR) mice (6–8 weeks) from Charles River Laboratories 
(Lyon, France) were acclimatised for 1 week. Six animals were housed per cage, on a 12 h light/dark 
cycle, at constant temperature (22 ± 2 °C). Standard food and tap water were provided ad libitum. Care 
of animals was undertaken in compliance with the European Community Directive 86/609/CEE for the 
use of laboratory animals and with the Autonomous Catalan law (Decret 214/1997). All experimental 
procedures were approved by the Almirall Ethics Committee.
Study design. APAP was dissolved in vehicle (0.5% methylcellulose and 0.1% Tween 80 in distilled 
water, 10 ml/kg) and administered by oral (po) gavage without prior fasting. Formulations were prepared 
daily. Some animals (n = 6) received a single dose of APAP or vehicle at 0 h (for 2 or 24 h). Other animals 
(n = 6) received subsequent administrations every 24 h of APAP or vehicle for 24, 48 or 72 h and were 
sacrificed 24 h after last administration. Mice received 250, 500 or 750 mg/kg of APAP; rats received 500, 
1000 or 1500 mg/kg of APAP. Based on clinical chemistry and histopathology analysis of liver injury, the 
rat 1500 mg/kg group was taken forward for further analysis. Terminal blood samples without previous 
fasting were collected from the retroorbital plexus under isoflurane anaesthesia (4% induction, 1.5–3% 
maintenance). Blood samples were centrifuged for 10 min at 3000 rpm, serum collected and stored at 
− 80 °C. Immediately after blood collection, animals were exsanguinated by cutting the abdominal aorta 
under isoflurane anaesthesia.
Toxicological assessment. A Synchron Clinical System cx7® (Beckman, Brea, CA) was used to 
determine ALT (IU/L) and AST ( IU/L). Samples of liver were frozen in liquid nitrogen before stor-
age at − 80 °C. The hepatic median lobe was formalin-fixed and embedded in paraffin, sectioned and 
stained with haematoxylin and eosin (H&E) for histological blind examination under light microscopy. 
Percentage of live cells was assessed in a complete section from each animal, and data expressed as 
mean ± standard error of mean (SEM).
NFE2L2(−/−) study. All experiments were undertaken in accordance with criteria outlined in a 
licence granted under the Animals (Scientific Procedures) Act 1986, and approved by the Animal Ethics 
Committee of the University of Liverpool. Generation of the NFE2L2 knockout mouse and genotyping 
of progeny have been described elsewhere15,16. Non-fasted male littermate NFE2L2(+/+) and NFE2L2(−/−) 
mice (C57BL6J background, 10–12 weeks of age) were used throughout the study. Mice were housed 
between 19 °C–23 °C, on a 12 h light/dark cycle, and given access to food and water ad libitum. Dosing 
began at 10 am each day and APAP was freshly prepared in warmed saline (0.9%). Pilot dose ranging 
studies confirmed the dose dependent nature of APAP-induced hepatotoxicity. In order to explore both 
the changes occurring during the pre-treatment phase and the effects of pre-treatment on susceptibility 
to a toxic challenge, two independent groups of mice were used:
NFE2L2(+/+) and NFE2L2(−/−) mice received increasing daily doses of APAP (2 × 150 mg/kg, 
2 × 300 mg/kg, 2 × 450 mg/kg, 2 × 600 mg/kg, i.p.) over 8 days, or vehicle control (n = 4). On day 9 mice 
were challenged with 1000 mg/kg APAP (i.p.) or vehicle (n = 4–8). Mice were culled 5 h after the final 
dose by exposure to a rising concentration of CO2 followed by cervical dislocation.
iTRAQ labelling and mass spectrometric analysis of liver homogenates. Rat liver samples 
(n = 4 animals per time-point, 1500 mg/kg group, ~100 mg wet weight) were homogenised in 0.5 M tri-
ethylammonium bicarbonate/0.1% SDS using a Mixer Mill 220 (Retsch, Haan, Germany), and centri-
fuged at 14000 g for 10 min. iTRAQ tagging and analysis was performed as described previously39.
iTRAQ protein identification and statistical analyses. Liver samples from rats treated with APAP 
or vehicle control were analysed across four iTRAQ runs. Data analysis was performed using ProteinPilot 
(Version 3, Life Technologies, Paisley, UK). The SwissProt database was searched with a confidence inter-
val of 95%, and screened in reverse to facilitate false discovery rate analysis. Proteins identified from 
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peptides with > 95% confidence and global false discovery rate of < 1% were included in the statistical 
analysis (1169 proteins).
Mean fold changes were calculated using the limma package within the R programming environment 
(Team, 2005) and analysis conducted on the logged fold-change values. Unadjusted (raw) p values and 
p values following FDR correction for multiple testing were determined.
Ontology and pathway analysis. Pathway analysis was performed using Ingenuity Pathway Analysis 
(Qiagen, Venlo, Netherlands). Ingenuity successfully mapped 1163/1169 proteins to pathways. At each 
timepoint, a ‘Core Analysis’ was performed on all proteins that were differentially expressed compared 
to control animals (raw p < 0.05) using the ‘Ingenuity Knowledge Base (Gene Only) Background’. The 
canonical pathways that were statistically significantly altered at each timepoint were compared using 
the ‘Comparison Analysis’ function.
Western immunoblotting. Buffered homogenates of standardised protein concentration (n = 4) were 
run on polyacrylamide gel, transferred onto nitrocellulose membrane (GE Healthcare, Little Chalfont, 
UK) and visualised using Western Lightning Plus ECL (Perkin Elmer, Waltham, MA). Proteins were 
normalised to actin. For GLUL, equal protein loading was confirmed using a Ponceau S stain.
Enzyme activity. Microsomes were prepared from livers of animals assigned to 2 h vehicle con-
trol, 48 h APAP (repeat exposure with toxicity) or 96 h APAP (repeat exposure, no toxicity) groups by 
homogenisation and ultracentrifugation, quantified using the Lowry method40, snap frozen and stored 
at − 80 °C until required. Microsomes from individual animals were incubated with either APAP (1 mM, 
100 uM or 10 uM for up to 4 h) or the CYP2E1 probe chlorzoxazone (1 uM for up to 90 mins) at 37 °C in 
a shaking water bath. Reactions were stopped with the addition of equal volumes of ice cold acetonitrile 
containing evaporation standard fluconazole and stored at − 80 °C until analysis by HPLC-MS.
Analysis by HPLC-MS/MS. Test samples were treated with acetonitrile, to remove matrix-based inter-
ferences. They were diluted with water prior to analysis by LC-MS/MS on a Sciex API 4000 (Warrington, 
UK) equipped with a Turbo V™ electrospray source (ESI). The gradients were based on mobile phases 
containing 0.1% v/v formic acid in both water (A) and acetonitrile (B).
Measurement of chlorzoxazone and its putative major metabolite, 6-hydroxy chlorzoxaz-
one. The separation was performed on a 2.7 μ M Halo® C18 column (50 × 2.1 mm ID) obtained from 
HiChrom (Reading, UK), and at a temperature of 40 °C and a flow-rate of 0.6 mL min−1. The following 
gradient was used: 0 min 5% B, 0.5 min 5% B, 1.5 min 95% B, 2 min 95% B, 2.1 min 5% B and 2.6 min 
5% B. D4-diclofenac was employed as the internal standard. The MS was operated in negative ion mode.
Measurement of APAP and its major metabolites. Separations were performed on a 2.6 μ m 
Kinetex® XB-C18 column (50 × 2.1 mm ID) obtained from Phenomenex (Macclesfield, UK), at a tem-
perature of 40 °C and a flow-rate of 0.5 mL min−1. The following gradient was used: 0 min 0% B, 0.3 min 
0% B then 2.3 min 50% B. The column was flushed with 100% B, and then returned to 0% B using a 
flow-rate of 0.7 mL min−1, giving a programmed cycle time of 4.2 minutes. A panel of deuterated internal 
standards was employed. The MS was operated in negative ion mode for measuring all but one of the 
putative major metabolites and high concentrations of APAP. It was operated in positive ion mode for 
measuring the remaining metabolite and low concentrations of APAP.
CYP2E1 localisation via immunohistochemistry. Immunohistochemical staining for CYP2E1 
was performed on formalin-fixed, paraffin-embedded liver sections of 3 μ m. Sections were mounted on 
poly-L-lysine coated slides, air-dried, deparaffinized and rehydrated. Slides were incubated with rabbit 
anti CYP2E1 antibody in 20% NGS/TBS-T. Secondary antibody was SignalStain® Boost IHC Detection 
Reagent (HRP, rabbit; Cell Signalling Technology, Beverly, MA, USA). The reaction was developed using 
3′, 3′ -diaminobenzidine tetrahydrochloride. Sections were counterstained with Harris haematoxylin.
Data evaluation and statistical analysis. Clinical chemistry data are expressed as mean ± SEM 
(n = 6). Serum ALT and AST data for vehicle- and APAP-treated animals were compared to time-matched 
controls by one-way ANOVA with Tukey’s post-hoc test using GraphPad PRISM (version 6.03 for 
Windows, GraphPad Software, San Diego, CA). Western immunoblotting data were analysed using 
a one-way ANOVA with Dunnetts post-hoc test. Microsomal data were analysed using an ordinary 
two-way ANOVA with Dunnett’s post-hoc test.
Literature estimates for Km are reported to be 30–300 times larger41,42 than the CZX concentration 
considered (1 uM) so we were able to adopt linear kinetics for CYP2E1 activity (enzyme velocity = α [S], 
where [S] = CZX concentration and α = Vmax/Km) instead of the full nonlinear Michaelis-Menten form. 
Solving the resulting first order ordinary differential equation then yields the following expression for 
6′-OH CZX formation versus time (using notation [P](t) to denote concentration at time t (min)): [P]
(t) = [S](0)(1 − exp(− α t/V)), where [S](0) = initial CZX concentration (1 uM) and V is the sample vol-
ume (0.02 ml). We used a Levenberg Marquardt (non-linear regression) algorithm to then find best 
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fit values for α = Vmax/Km for the control, 48 and 96 hour cases. Note that, in each case, our estimates 
for α = Vmax/Km were found to lie within acceptable literature ranges. Under the assumption that 
enzyme-substrate binding affinity (1/Km) is unaffected by microsomal conditions, ratios of α estimates 
were then used to compare relative enzyme activities.
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